Loading viewer...
investor_presentation
Format: PDF investor_presentation
Organon investor presentation dated October 2022.
Q3 2022 Earnings OrganonDisclaimer statement
Safe Harbor for Forward-Looking Statements
Except for historical information herein, this presentation includes “forward-looking statements” within the meaning of the safe harbor provisions of the
U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about management’s expectations about Organon’s future
financial performance and prospects. Forward-looking statements may be identified by words such as “expects,” “intends,” “anticipates,” “plans,”
“believes,” “seeks,” “estimates,” “will” or words of similar meaning. These statements are based upon the current beliefs and expectations of the
company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties
materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include, but are not limited
to, an inability to execute on our business development strategy or realize the benefits of our planned acquisitions; general economic factors, including
interest rate and currency exchange rate fluctuations; general industry conditions and competition; the impact of the ongoing COVID-19 pandemic and
emergence of variant strains; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global
trends toward health care cost containment; technological advances; new products and patents attained by competitors; challenges inherent in new
product development, including obtaining regulatory approval; the company’s ability to accurately predict its future financial results and performance; the
company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and
sovereign risk; difficulties developing and sustaining relationships with commercial counterparties; dependence on the effectiveness of the company’s
patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company
undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional
factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s filings with the
Securities and Exchange Commission (SEC), including the company's Annual Report on Form 10-K for the year ended December 31, 2021 and
subsequent SEC filings, available at the SEC’s Internet site (www.sec.gov).This text should be viewed in conjunction with Organon’s Q3 2022 earnings call
2Disclaimer statement, cont.
Non-GAAP Information
This presentation contains “non-GAAP financial measures,” which are financial measures that either exclude or include amounts that are not
Preview truncated — download the full document for the complete content.
investor_presentation
25 Pages
investor_presentation
24 Pages
Tennant Company